Glucocorticoid-induced osteoporosis

1. <div><p>Бащинский С.Е. Разработка клинических практических руководств с позиций доказательной медицины. Учебное пособие для врачей и организаторов здравоохранения. Медиа Сфера, М., 2004, 46-47.</p><p>Van Staa Т.Р., Leufkens H.G.M., Abenhaim L. et al. Use of oral corticosteroids in the United Kingdom. Q. J. Med., 2000, 93, 105-111</p><p>Hooyman J.R., Melton L.J., Nelson A.M. et al. Fractures after rheumatoid arthritis. A population-based study. Arthr. Rheum., 1984, 27, 12, 1353-1361</p><p>Cooper C„ Coupland C., Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann. Rheum. Dis., 1995, 54, 49-52</p><p>Gennari C., Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif. Tiss. Int., 1985, 37, 592-593</p><p>Lukert B.P., Johnson B.E., Robinson R.G. Estrogen and progesterone replacement therapy reduces glucocorticoid- induced bone loss. J. Bone Miner. Res., 1992. 7, 1063-1069</p><p>Rizzato G., Tosi G., Schiraldi G. et al. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis, 1988, 5, 99-103</p><p>Laan R.F.J.M., Buijs W.C.A.M, van Erning L.J.T.O. et al. Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif. Tiss. Int., 1993, 52. 5-9</p><p>van Staa T.P., Leufkens H.G.M., Cooper C. The epidemiology of corticosteroid-induced osteoporosis. Osteoporos. Int., 2002, 13, 777-787</p><p>van Staa T.P, Leufkens H.G.M., Abenhaim L. et al. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res., 2000, 15, 993-1000</p><p>Laan R.F.J.M., van Riel P.L.C.M., van de Putte L.B.A. et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoidarthritis- a randomized, controlled study. Ann. Intern. Med., 1993, 119, 963-968</p><p>Johnell O., de Laet C., Johansson H. et al. Oral corticosteroids increase fracture risk independently of BMD. Osteoporos. Int., 2002, 13, (suppl 1), S14</p><p>Luengo М., Picado C., Delrio L. et al. Vertebral fractures in steroid dependent asthma and involutional osneoporosis - a comparative study. Thorax, 1991, 46, 803-806</p><p>Harris S.T., Watts N.B., Genant H.K. et al. Effects of rise- dronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA, 1999, 282, 1344-1352</p><p>Reginster J.Y., Minne H.W., Sorensen O.H. et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int., 2000, 11, 83-91</p><p>Wallach S., Cohen S., Reid D.M. et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tiss. Int., 2000, 67, 277285.</p><p>McClung M.R., Geusens P., Miller P.D. et al. Effects of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med., 2001, 344, 333-340</p><p>van Staa T.P., Laan R.F., Barton I.P. et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthr. Rheum., 2003, 48(11), 3224-3229</p><p>Glucocorticoid-induced osteoporosis. Royal College of Physicians of London, 2002, //www.rcplondon.ac.uk</p><p>American College of Rheumatology. Task force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthr. Rheum., 1996. 39, 1791-1801</p><p>Glucocorticoid-induced osteoporosis: guidelines for the prevention and treatment. Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicians. London, 2003</p><p>Gotzsche P.C., Johansen H.K. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. (Cochrane Review). The Cochrane Library, Issue I, 2004</p><p>Criswell L.A., Saag K.G., Sems K.M. et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. (Cochrane Review). The Cochrane Library, Issue I, 2004</p><p>Adachi J.D., Olszynski W.P., Hanley D.A. et al. Management of corticosteroid-induced osteoporosis. Semin. Arthr. Rheum., 2000, 29(4), 228-251</p><p>Jones A., Fay J.K., Burret M. al. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. The Cochrane Library, Issue 1, 2004</p><p>Johnell O., Pauwels R., Lofdahl C.G. et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur. Respir. J., 2002, 19(6), 1058-1063.</p><p>Suissa S., Baltean М., Kremer R. et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am. J. Respir. Crit. Care Med., 2004, 169, 83-88</p><p>Hubbard R.B., Smith P,, Smeetli L. et al. Inhaled corticosteroids and hip fracture. A population-based case-control study. Am. Respir. Crit. Care Med., 2002, 166, 1563-1566.</p><p>van Staa T.P., Leufkens H.G., Cooper C. Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res., 2001, 16, 581-588</p><p>van Staa T.P., Bishop N., Leufkens H.G. et al. Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos. Int., 2004, 21 [Epub ahead of print]</p><p>Homik J., Cranney A., Shea B. et al. Bisphosphonates for steroid induced osteoporosis (Cochrane Review). The Cochrane Library, Issue I, 2004</p><p>Gonnelli S., Rottoli P., Cepollaro C. et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif. Tiss. Int., 1997, 61, 382-385</p><p>Saag K.G., Emkey R., Schnitzer T.J. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N. Engl. J. Med., 1998, 339, 292-299</p><p>Adachi J.D., Saag K.G., Delmas P.D. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthr. Rheum., 2001, 44, 202-211</p><p>Sambrook F.N., Kotowicz М., Nash P. et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J. Bone Miner. Res., 2003.18(5), 919-924</p><p>Lau E.M., Woo J., Chan Y.H. et al. Alendronate for the prevention of bone loss in patients on inhaled steroid therapy. Bone, 2001, 29(6), 506-510</p><p>Adachi J.D., Bensen W.G., Bell M.J. et al. Salmon calcitonin nasal spray in the prevention of corticosteroid- induced osteoporosis. Br. J. Rheumatol., 1997, 36, 255 -259</p><p>Healey J.H., Paget S.A., Williams-Russo P. et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif.Tiss. Int., 1996, 58-73</p><p>Kotanieemi A., Piiraainen H., Paimela L. et al. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J. Rheumtol., 1996, 23, 1875-1979</p><p>Luengo M, Picado C., Del Rio L, et al. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. Am. Rev. Respir. Dis., 1990, 142, 104-107</p><p>Luengo М., Pons F., Martinez de Osaba M.J. et al. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma. A two year follow up study. Thorax, 1994, 49, 1099-1102</p><p>Ringe J.D., Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. J. Clin. Pharmacol., 1987, 33, 35-39</p><p>Healey J.H., Paget S.A., Williams-Russo P. et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif. Tiss., 1996, 58, 73-80</p><p>Cranney A., Welch V., Adachiet J.D. al. Calcitonin for preventing and treating corticosteroid-induced osteoporosis. (Cochrane Review). The Cochrane Library, Issue I, 2004</p><p>Lyritis G.P., Tsakalakos N. Magiasis B. et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double, placebo-controlled clinical study. Calcif. Tiss. Int., 1991, 49, 369-372</p><p>Gennari C., Chirchietti S.M., Piolini M. et al. Analgesic activity of salmon and human calcitonin against cancer: a double blind, placebo-controlled clinical study. Curr. Ther. Res., 1985, 38, 298-308</p><p>Pontiroli A.E., Pajetta E., Scaglia L. et al. Analgetic effect of intranasal and intramuscular salmon calcitonin in postmenopausal osteoporosis: a double-blind, double-placebo study. Aging. Clin. Exp. Res., 1994, 6, 459-463</p><p>Pun K.K., Chan L.W. Analgesic effect of intranasal salmon calcitonin in treatment of osteoporotic vertebral fractures. Clin. Ther., 1989, II, 205-209</p><p>Homik J., Suarez-Almazor M.E., Shea B. et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. (Cochrane Review). The Cochrane Library, Issue I, 2004</p><p>Reginster J.Y., Kuntz D., Verdickt W. et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos. М., 1999, 9, 75-81</p><p>Lakatos P., Nagy Z., Kiss L. et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. J. Rheumatol., 2000, 59(suppl I), 48-52</p><p>Ringe J.D., Dorst A., Faber H. et al. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol. Int., 2004, 24(2), 63-70</p><p>Dequeker J., Borghs H., van Cleemput J. et al. Transplantation osteoporosis and corticosteroidinduced osteoporosis in autoimmune diseases: experience with alfacalcidol. Z. Rheumatol., 2000, 59(suppl -7)</p><p>Yamada H. Long-term effect of la-hydroxyvitamm D, calcium and thiazide administration on glucocorticoid-induced osteoporosis. Folia Endocrinol. Jap., 1969, 65, 603-614</p><p>Dykman T.R., Haralson K.M., Gluck O.S. et al. Effect of oral 1,25-hydroxyvitamin D and calcium on glucocorticoid- induced osteopenia in patients with rheumatic diseases. Arthr. Rheum., 1984, 27, 1336-1343</p><p>Rickers H., Deding A., Christiansen C. et al. Corticosteroidinduced osteopenia and vitamin D metabolism. Effect of vitamin D2, calcium phosphate and sodium fluoride administration. Clin. Endocrinol., 1932, 16, 409-415</p><p>Rizzoli R., Chevaliey Т., Slosman D. et al. Sodium mono- fluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporos. Int., 1995, 5, 39-46</p><p>Lippuner K., Haller B.. Casez J.P. et al. Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticoids: a prospective randomised, doubleblind study. Miner. Electrolyte Metab., 1996, 22, 207-213</p><p>Guaydier-Souquieres G., Kctzki P.O., Sabatier J.P. et al. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomised study. Qsteoporos. Int., 1996, 6, 171-177</p><p>Lems W.F., Jacobs J.W.G., Bijlsma J.W.J. et al. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid-induced osteoporosis'? Ann. Rheum. Dis., 1997, 56, 357-363</p><p>Lems W.F., jacobs J.W.G., Bijlsma J.W.J. et al. Effect of sodium fluonde on the prevention of corticosteroid-induced osteoporosis. Ostecporos. Int., 1997, 7, 575-582</p><p>Von Tirpitz C., Klaus J., Bruckel J. et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur. J. Gastroenterol. Hepatol., 2000, 1219-1224</p><p>Haguenauer D., Welch V., Shea B. et al. Fluoride for the treatment of postmenopausal osteoporotic fractures; a meta-analysis. Osteoporos. Int., 2000, II, 727-738</p><p>Lane N.E., Sanchez S., Modm G.W. et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled trial. J. Clin. Invest., 1998, 102, I, 627-633</p><p>Lane N.E., Sanchez S., Genant H.K. et al. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with osteoporosis. Osteoporos. Int., 2000, 11, 434-442</p><p>Lane N.E., Sanchez S., Modm G.W. et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in. glucocorticoid-induced osteoporosis, results of a randomized controlled clinical trial. J. Bone Miner. Res., 2000,15, 944</p><p>Reid J.R., Wattie D.J., Evans M.C. et al. Testosterone therapy in glucocoriticoid-treated men. Arch., 1996, 156, 1173-1177</p><p>Hall G.M., Daniels М., Doyle D.V. et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthr. Rheum., 1994, 37, 499-505</p><p>Coombes G.M., Bax B.E., Eastell R. et al. Treatment of corticosteroid-induced osteoporosis using Tirolone- a randomised, double-blind, placebo-controlled trial. J. Bone Miner. Res., 2000, 15(supp! 1), S311</p><p>Choi W.H. The effect of 1.25(OH)2D (calcitriol) on glucocorticoid-induced osteoporosis. J. Bone, 1999, 14(suppl), 34-39</p></div><br />